Compare Appian Corp (APPN) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Appian Corp vs Revvity Inc — how do they compare? Appian Corp trades at $34.63 (market cap $2.54B), while Revvity Inc trades at $116.39 (market cap $12.91B). The key difference: Revvity Inc is far larger — about 5.1× Appian Corp's market cap, and Revvity Inc pays a 0.24% dividend while Appian Corp pays none. Which is the better fit depends on your goals.
| APPN | RVTY | |
|---|---|---|
Market Cap | $2.54B | $12.91B |
Sector | Technology | Technology |
52-Week High | $45.64 | $117.75 |
52-Week Low | $18.72 | $82.26 |
Enterprise Value | $2.67B | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Appian (APPN) trades at $34.42, down 3.26% on the day, following recent earnings beats but amid broader software stock volatility. The stock shows a bullish technical trend with moving averages supporting upside, though oscillators indicate overbought conditions. Fundamentally, revenue growth remains strong with 2025 revenue at $726.94 million and a return to positive net income of $1.23 million, yet profitability metrics like ROE at -936.62% highlight ongoing challenges. Recent news highlights AI-driven partnerships and enterprise demand as key growth catalysts.
The outlook is mixed: analyst consensus is cautious with a hold-heavy rating (63.16% hold) and a $32.50 price target below the current price, signaling limited near-term upside. Risks include high debt levels, negative equity, and competitive pressures in low-code software. Investment appeal hinges on sustained AI adoption and margin improvement, but volatility and weak shareholder equity pose significant risks.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
